To explore and analyze the clinical efficacy and safety of doxazosin mesylate sustained release tablets in the treatment of postoperative bladder spasm after electroprostatectomy (TURP).

A total of 110 patients receiving TURP admitted to our hospital from March 2020 to May 2022 were selected and randomly divided into control and observation groups, with 55 cases in each group. The control group was treated with doxazosin mesylate sustained release tablets after TURP operation, and the observation group was treated with diclofenac sodium supposal anal plug on the basis of oral treatment. The results of occurrence time and frequency of postoperative bladder spasm, visual analog scale (VAS), duration of bladder flushing solution dilution, catheter indwelling time, postoperative hospital stay and incidence of adverse reactions were compared between the two groups.

In the observation group, the duration of postoperative bladder spasm was shorter, the frequency was less, and the VAS score was lower than that in the control group 0 to 24 h, 24 to 78 h and 48 to 72 h after surgery, with statistically significant differences (P<0.05). Compared with the control group, the observation group had a significantly shorter duration of bladder flushing fluid dilution, catheter indwelling time and postoperative hospital stay (P<0.05). There was no significant difference in the incidence of postoperative adverse reactions between the two groups (P>0.05).

The application of doxazosin mesylate combined with diclofenac sodium in the treatment of postoperative bladder spasm after TURP has a singnificant effectwith high safety. It can effectively shorten the occurrence time of bladder spasm, reduce the frequency of incidence, relieve the degree of pain and shorten the duration of clinical symptoms. There is no obvious adverse reactions during medication.